Nothing Special   »   [go: up one dir, main page]

JP3176137B2 - Biuret derivative - Google Patents

Biuret derivative

Info

Publication number
JP3176137B2
JP3176137B2 JP21447292A JP21447292A JP3176137B2 JP 3176137 B2 JP3176137 B2 JP 3176137B2 JP 21447292 A JP21447292 A JP 21447292A JP 21447292 A JP21447292 A JP 21447292A JP 3176137 B2 JP3176137 B2 JP 3176137B2
Authority
JP
Japan
Prior art keywords
compound
acid
biuret
benzyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP21447292A
Other languages
Japanese (ja)
Other versions
JPH0616621A (en
Inventor
宙造 岩田
徹明 田中
Original Assignee
大正製薬株式会社
日本水産株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大正製薬株式会社, 日本水産株式会社 filed Critical 大正製薬株式会社
Priority to JP21447292A priority Critical patent/JP3176137B2/en
Publication of JPH0616621A publication Critical patent/JPH0616621A/en
Application granted granted Critical
Publication of JP3176137B2 publication Critical patent/JP3176137B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【産業上の利用分野】本発明は神経細胞の維持に関与す
る神経栄養因子活性を有するビウレット誘導体に関す
る。
The present invention relates to a biuret derivative having a neurotrophic factor activity involved in maintenance of nerve cells.

【0002】[0002]

【従来の技術】近年増加しつつあるアルツハイマー型老
年痴呆においては、大脳基底核神経細胞であるアセチル
コリン作動性神経の変性や脱落が記憶障害、知的活動低
下等に深く関わっており{R.J.Whitehous
等,サイエンス(Science),第215巻,第1
237頁(1982年)}、その結果、脳において情報
伝達の働きをしている神経伝達物質の合成に異常をきた
して、痴呆症状が進行していくといわれている。これら
の点からコリンエステラーゼ阻害、アセチルコリン神経
活動賦活、ムスカリン性アセチルコリン受容体(M
アゴニスト等のアセチルコリンをターゲットとした薬物
の研究が進められている。
In Alzheimer's senile dementia, which has been increasing in recent years, degeneration and loss of acetylcholinergic nerves, which are basal ganglia neurons, are deeply related to memory impairment, decreased intellectual activity, and the like. J. Whitehouse
Et al., Science, Vol. 215, No. 1
237 (1982)} As a result, it is said that as a result, abnormalities occur in the synthesis of neurotransmitters that function to transmit information in the brain, and dementia symptoms progress. From these points, cholinesterase inhibition, activation of acetylcholine nerve activity, muscarinic acetylcholine receptor (M 1 )
Research on drugs targeting acetylcholine, such as agonists, is in progress.

【0003】一方、神経細胞の維持に関係する栄養因子
FGF,EGF,NGF等の研究も進められている。こ
れらは基本的には特定の細胞に作用し、未分化の神経細
胞の分化、成長や成熟した神経細胞の生存、機能維持に
重要な役割を果たすと考えられている。中でもNGF
(神経成長因子)は細胞の突起を延ばし、神経細胞の発
生から死に至るまでの間に何らかの作用を及ぼすものと
考えられ、アルツハイマー病薬としての可能性も検討さ
れている。しかしながら、本発明の化合物には上記の神
経栄養因子活性については報告されていない。
[0003] On the other hand, research on trophic factors FGF, EGF, NGF and the like related to the maintenance of nerve cells is also in progress. These act basically on specific cells and are thought to play an important role in the differentiation of undifferentiated neurons, the survival of mature and mature neurons, and the maintenance of function. Among them, NGF
(Nerve growth factor) is thought to extend the process of cells and exert some action during the period from the generation of nerve cells to death, and their potential as Alzheimer's disease drugs is also being studied. However, the compounds of the present invention have not been reported for the above-mentioned neurotrophic factor activity.

【0004】[0004]

【発明が解決しようとする課題】本発明は、神経細胞の
維持に関与する神経栄養因子活性を有する新規な化合物
を提供することにある。
An object of the present invention is to provide a novel compound having a neurotrophic factor activity involved in maintenance of nerve cells.

【0005】[0005]

【課題を解決するための手段】本発明者らはビウレット
構造を有する化合物について鋭意検討した結果、神経栄
養因子活性を有する新規のビウレット誘導体を見出し本
発明を完成した。
Means for Solving the Problems As a result of intensive studies on compounds having a biuret structure, the present inventors have found a novel biuret derivative having a neurotrophic factor activity and completed the present invention.

【0006】以下、本発明を説明する。本発明は、式
[1]
Hereinafter, the present invention will be described. The present invention provides a compound of the formula [1]

【化2】 (化2中、R,Rは炭素数1〜5のアルキル基また
はベンジル基である。)で表されるビウレット誘導体お
よびその塩。本発明においてアルキル基とは直鎖状また
は分枝鎖状のものであり、例えばメチル基、エチル基、
プロピル基、イソプロピル基、ブチル基、ペンチル基な
どである。
Embedded image (Wherein R 1 and R 2 are an alkyl group having 1 to 5 carbon atoms or a benzyl group) and salts thereof. In the present invention, the alkyl group is a linear or branched one, for example, a methyl group, an ethyl group,
Propyl, isopropyl, butyl, pentyl and the like.

【0007】また、本発明の式[1]で示される化合物
の塩とは薬理学により許容されるものを意味し、例えば
硫酸、塩酸、燐酸などの鉱酸との塩、酢酸、乳酸、酒石
酸、フマル酸、マレイン酸、トリフルオロ酢酸、メタン
スルホン酸などの有機酸との塩が挙げられる。
The salt of the compound represented by the formula [1] of the present invention means a salt acceptable by pharmacology, for example, a salt with a mineral acid such as sulfuric acid, hydrochloric acid and phosphoric acid, acetic acid, lactic acid and tartaric acid , Fumaric acid, maleic acid, trifluoroacetic acid, and salts with organic acids such as methanesulfonic acid.

【0008】式[1]の化合物は、例えば以下の方法に
より得ることが出来る。
The compound of the formula [1] can be obtained, for example, by the following method.

【化3】 Embedded image

【0009】アルコール(例えばC〜Cの低級アル
コールまたはベンジルアルコール)とアルカリ金属(N
a,K等)またはアルカリ金属水素化物(NaH,Li
H,KH等)で調製したアルコキシド(ROM,式
中、Rは前記と同意義でありMはアルカリ金属であ
る。)と3位がRで置換された式[2]の2−シアノ
イミノチアゾリジン(特開昭48−91064号公報に
記載の方法に準じて合成できる)を溶媒(例えばベンゼ
ン、テトラヒドロフラン、N,N−ジメチルホルムアミ
ド、ジメチルスルホキシドまたはこれらの混合物)を用
い加温することにより、式[4]のシアノウレア誘導体
のアルカリ金属塩を得る。このものを水にとかした後、
酸(例えば塩酸、硫酸、酢酸等)を加え加熱還流するこ
とにより式[1]のビウレット誘導体を得る。
An alcohol (for example, a C 1 -C 5 lower alcohol or benzyl alcohol) and an alkali metal (N
a, K, etc.) or alkali metal hydrides (NaH, Li
H, KH, etc.) (R 2 OM, wherein R 2 is as defined above and M is an alkali metal) and 2 of the formula [2] wherein 3-position is substituted by R 2 . -Cyanoiminothiazolidine (which can be synthesized according to the method described in JP-A-48-91064) is heated using a solvent (for example, benzene, tetrahydrofuran, N, N-dimethylformamide, dimethylsulfoxide or a mixture thereof). Thereby, an alkali metal salt of a cyanourea derivative of the formula [4] is obtained. After dissolving this thing in water,
An acid (eg, hydrochloric acid, sulfuric acid, acetic acid, etc.) is added and the mixture is heated under reflux to obtain a biuret derivative of the formula [1].

【0010】式[4]の化合物を得る際、DMF中80
℃で加温することが好ましい。更にこの反応において用
いたアルコキシドのアルキル基が硫黄原子に転位してい
ることが新たに判明した。この反応は、アルコキシドが
2位へ付加後C(2)−S結合が選択的に開裂し、求核
性の高い式[3]のメルカプチドが生成すると考えられ
る。このものは、シアノイミノ基の電子吸引性のためO
−R結合が開裂しやすく、アルコキシル基のアルキル
基Rが硫黄原子に転位すると考えられる。N−シアノ
イミノチアゾリジンにおいては、この様な転位反応は知
られていない。
In obtaining the compound of the formula [4], 80
It is preferred to heat at ℃. Furthermore, it was newly found that the alkyl group of the alkoxide used in this reaction was rearranged to a sulfur atom. In this reaction, it is considered that the C (2) -S bond is selectively cleaved after addition of the alkoxide to the 2-position, and a mercaptide of the formula [3] having high nucleophilicity is generated. This is because of the electron-withdrawing property of the cyanoimino group.
It is considered that the —R 2 bond is easily cleaved and the alkyl group R 2 of the alkoxyl group is rearranged to a sulfur atom. Such a rearrangement reaction is not known for N-cyanoiminothiazolidine.

【0011】[0011]

【発明の効果】本発明により神経細胞の維持に関与する
神経栄養因子活性を示す化合物が提供された。
Industrial Applicability According to the present invention, there is provided a compound exhibiting a neurotrophic factor activity involved in maintenance of nerve cells.

【0012】[0012]

【実施例】次に、実施例および試験例を挙げて本発明を
さらに詳細に説明する。 実施例 窒素気流下、60%水素化ナトリウム(0.21g)を
DMF(5ml)に懸濁し、氷冷下ベンジルアルコール
(0.55ml)を時間をかけ摘下しアルコキシドとし
た。これに3−ベンジル−2−(N−シアノイミノ)チ
アゾリジン(1.09g)を加え80℃で4時間攪拌し
た。反応後、水0.5mlを加え溶媒を減圧留去し、残
渣をシリカゲルクロマトグラフィーに付し、クロロホル
ムーメタノール溶出画分によりN−シアノ−N’−ベン
ジル−N’−(2−ベンジルチオエチル)尿素ナトリウ
ム塩1.26gを得た。このものを水(5ml)に溶解
後、塩酸(5ml)を加え100℃で7分間加熱した。
反応後クロロホルム抽出した。溶媒留去後エタノールで
再結晶し1−ベンジル−1−(2−ベンジルチオエチ
ル)ビウレット(化合物C)0.67gを得た。 MS m/z 343 (C1821S) m.p. 107.5−108.0℃ H−NMR(CDCl) δ;2.59(2H,
t,J=7.2),3.39(2H,t,J=7.
2),3.72(2H,s),4.44(2H,s),
7.14−7.36(10H,m) IR(CHCl)cm−1;3550,3350,1
715,1680
Next, the present invention will be described in more detail with reference to examples and test examples. Example 60% sodium hydride (0.21 g) was suspended in DMF (5 ml) under a nitrogen stream, and benzyl alcohol (0.55 ml) was removed over time with ice cooling to obtain an alkoxide. To this was added 3-benzyl-2- (N-cyanoimino) thiazolidine (1.09 g), and the mixture was stirred at 80 ° C for 4 hours. After the reaction, 0.5 ml of water was added and the solvent was distilled off under reduced pressure. The residue was subjected to silica gel chromatography, and N-cyano-N′-benzyl-N ′-(2-benzylthioethyl) was eluted with a fraction eluted with chloroform-methanol. 1.) 1.26 g of urea sodium salt were obtained. This was dissolved in water (5 ml), hydrochloric acid (5 ml) was added, and the mixture was heated at 100 ° C. for 7 minutes.
After the reaction, chloroform extraction was performed. After the solvent was distilled off, the residue was recrystallized from ethanol to obtain 0.67 g of 1-benzyl-1- (2-benzylthioethyl) biuret (compound C). MS m / z 343 (C 18 H 21 N 3 O 2 S) m. p. 107.5-108.0 ° C 1 H-NMR (CDCl 3 ) δ; 2.59 (2H,
t, J = 7.2), 3.39 (2H, t, J = 7.
2), 3.72 (2H, s), 4.44 (2H, s),
7.14-7.36 (10H, m) IR ( CHCl 3) cm -1; 3550,3350,1
715, 1680

【0013】上記と同様にして、それぞれ対応する出発
物質から下記の化合物を得た。 1−ベンジル−1−(2−メチルチオエチル)ビウレッ
ト (化合物A) MS m/z 267 (C1217S) m.p. 92.0−93.g℃ (酢酸エチル−ヘキ
サンより再結晶) H−NMR(CDCl) δ;2.12 (3H,
s),2.53(2H,t,J=7.2),3.54
(2H,t,J=7.2),4.57(2H,s),
7.2−7.4(5H,m) IR(CHCl)cm−1;3500,3300,1
710,1680
In the same manner as above, the following compounds were obtained from the corresponding starting materials. 1-benzyl-1- (2-methylthioethyl) biuret (Compound A) MS m / z 267 ( C 12 H 17 N 3 O 2 S) m. p. 92.0-93. g ° C. (recrystallized from ethyl acetate-hexane) 1 H-NMR (CDCl 3 ) δ; 2.12 (3H,
s), 2.53 (2H, t, J = 7.2), 3.54
(2H, t, J = 7.2), 4.57 (2H, s),
7.2-7.4 (5H, m) IR ( CHCl 3) cm -1; 3500,3300,1
710,1680

【0014】1−ベンジル−1−(2−エチルチオエチ
ル)ビウレット (化合物B) MS m/z 281 (C1319S) m.p. 90.0−92.0℃ (酢酸エチル−ヘキ
サンより再結晶) H−NMR(CDCl) δ;1.24(3H,
t,J=7),2.55(2H,q,J=7),2.6
8(2H,t,J=7),3.53(2H,t,J=
7),4.57(2H,s),7.20−7.37(5
H,m) IR(CHCl)cm−1;3500,3330,1
715,1680
1-benzyl-1- (2-ethylthioethyl) biuret (Compound B) MS m / z 281 (C 13 H 19 N 3 O 2 S) m. p. 90.0-92.0 ° C. (recrystallized from ethyl acetate-hexane) 1 H-NMR (CDCl 3 ) δ; 1.24 (3H,
t, J = 7), 2.55 (2H, q, J = 7), 2.6
8 (2H, t, J = 7), 3.53 (2H, t, J =
7), 4.57 (2H, s), 7.20-7.37 (5
H, m) IR (CHCl 3 ) cm -1; 3500,3330,1
715, 1680

【0015】1−(2−エチルチオエチル)−1−メチ
ルビウレット (化合物D) MS m/z 205 (C15S) m.p. 92.0−93.0℃ (酢酸エチル−ヘキ
サンより再結晶) H−NMR(CDCl)δ;1.28(3H,t,
J=7),2.59(2H,q,J=7),2.71
(2H,t,J=7),3.01(3H,s),3.5
3(2H,t,J=7) IR(CHCl)cm−1;3500,3320,1
710,1670
1- (2-ethylthioethyl) -1-methylbiuret (Compound D) MS m / z 205 (C 7 H 15 N 3 O 2 S) m. p. 92.0-93.0 ° C. (recrystallized from ethyl acetate-hexane) 1 H-NMR (CDCl 3 ) δ; 1.28 (3H, t,
J = 7), 2.59 (2H, q, J = 7), 2.71.
(2H, t, J = 7), 3.01 (3H, s), 3.5
3 (2H, t, J = 7) IR (CHCl 3 ) cm −1 ; 3500, 3320, 1
710,1670

【0016】1−(2−ベンジルチオエチル)−1−メ
チルビウレット (化合物E) MS m/z 267 (C120NS) m.p. 133.0−133.5℃(酢酸エチル−ヘ
キサンより再結晶) H−NMR(CDCl)δ;2.58(2H,t,
J=7),2.90(3H,s),3.41(2H,
t,J=7),3.75(2H,s),7.26−7.
34(5H,brs) IR(CHCl)cm−1;3500,3300,1
710,1670
[0016] 1- (2-benzyl-thio-ethyl) -1-methyl-biuret (Compound E) MS m / z 267 ( C 12 H 2 0N 3 O 2 S) m. p. 133.0-133.5 ° C (recrystallized from ethyl acetate-hexane) 1 H-NMR (CDCl 3 ) δ; 2.58 (2H, t,
J = 7), 2.90 (3H, s), 3.41 (2H,
t, J = 7), 3.75 (2H, s), 7.26-7.
34 (5H, brs) IR (CHCl 3 ) cm −1 ; 3500, 3300, 1
710,1670

【00017】試験例 神経栄養因子活性の測定 ラットの胎児の大脳皮質より調製した細胞をポリエチレ
ンイミンを塗布した24マルチウエルプレートに1.6
1×10個の細胞を播種し、無血清培地DF(ダルベ
ッコの最小必須培地およびハムF−12培地を等量混合
した物)を加え、24時間5%炭酸ガス培養槽中37℃
で培養した。その後、被検化合物を所定濃度に調製した
DF培地に置換し72時間同条件下にて培養を継続し
た。培養終了後、培養液を除去し所定の濃度に調製した
MTT{3−(4,5−ジメチルチアゾール−2−イ
ル)−2,5−ジフェニルテトラゾリウムブロミド}溶
液を加えた。4時間培養後上清を除去し培養神経細胞を
DMSOにて抽出その吸光度を測定した。一方、被検化
合物を加えないで培養したときの吸光度を100とし神
経栄養因子活性とした。上記方法を用いて、得た結果を
表1に示す。
Test Example Measurement of Neurotrophic Factor Activity Cells prepared from rat cerebral cortex were placed in a polyethyleneimine-coated 24-multiwell plate at 1.6.
1 × 10 6 cells were seeded, and a serum-free medium DF (a mixture of Dulbecco's minimum essential medium and Ham F-12 medium in an equal amount) was added thereto, and the mixture was incubated at 37 ° C. in a 5% carbon dioxide gas culture tank for 24 hours.
And cultured. Thereafter, the test compound was replaced with a DF medium adjusted to a predetermined concentration, and the culture was continued under the same conditions for 72 hours. After completion of the culture, the culture solution was removed, and an MTT {3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide} solution adjusted to a predetermined concentration was added. After culturing for 4 hours, the supernatant was removed, and the cultured neurons were extracted with DMSO and the absorbance was measured. On the other hand, the absorbance at the time of culturing without adding the test compound was taken as 100, and the activity was regarded as neurotrophic factor activity. Table 1 shows the results obtained using the above method.

【0018】[0018]

【表1】 [Table 1]

───────────────────────────────────────────────────── フロントページの続き (56)参考文献 米国特許3671501(US,A) Bull.Soc.Chim.Fr. (1974),7−8,Pt.2,1497− 1505 (58)調査した分野(Int.Cl.7,DB名) C07C 323/00 A61K 31/00 CA(STN) REGISTRY(STN)────────────────────────────────────────────────── ─── Continuation of front page (56) Reference US Pat. No. 3,671,501 (US, A) Bull. Soc. Chim. Fr. (1974), 7-8, Pt. 2,1497-1505 (58) Fields investigated (Int. Cl. 7 , DB name) C07C 323/00 A61K 31/00 CA (STN) REGISTRY (STN)

Claims (1)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】 【化1】 (化1中、RおよびRは炭素数1〜5のアルキル基
またはベンジル基である。)で表されるビウレット誘導
体およびその塩。
[Claim 1] (In the formula 1, R 1 and R 2 are an alkyl group having 1 to 5 carbon atoms or a benzyl group.) And a salt thereof.
JP21447292A 1992-07-02 1992-07-02 Biuret derivative Expired - Fee Related JP3176137B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP21447292A JP3176137B2 (en) 1992-07-02 1992-07-02 Biuret derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP21447292A JP3176137B2 (en) 1992-07-02 1992-07-02 Biuret derivative

Publications (2)

Publication Number Publication Date
JPH0616621A JPH0616621A (en) 1994-01-25
JP3176137B2 true JP3176137B2 (en) 2001-06-11

Family

ID=16656295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP21447292A Expired - Fee Related JP3176137B2 (en) 1992-07-02 1992-07-02 Biuret derivative

Country Status (1)

Country Link
JP (1) JP3176137B2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0312023A (en) 2002-06-27 2005-03-22 Novo Nordisk As Compound, glucose kinase activating compound, method for preventing hypoglycemia, use of a compound, and pharmaceutical composition
CN102516240A (en) 2004-01-06 2012-06-27 诺和诺德公司 Heteroaryl-ureas and their use as glucokinase activators
ATE547396T1 (en) 2005-07-08 2012-03-15 Novo Nordisk As DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS
EP1904467B1 (en) 2005-07-14 2013-05-01 Novo Nordisk A/S Urea glucokinase activators
WO2008084043A1 (en) 2007-01-09 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
EP2099777B1 (en) 2007-01-11 2015-08-12 Novo Nordisk A/S Urea glucokinase activators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bull.Soc.Chim.Fr.(1974),7−8,Pt.2,1497−1505

Also Published As

Publication number Publication date
JPH0616621A (en) 1994-01-25

Similar Documents

Publication Publication Date Title
KR101861981B1 (en) Method for producing methyl-(4,6-diamino-2-(1-(2-fluorobenzyl)-1h-pyrazolo(3,4-b)pyridino-3-yl)pyrimidino-5-yl)methylcarbamate and its purification for use thereof as pharmaceutical substance
DE19942809A1 (en) Process for the preparation of substituted pyrimidine derivatives
US20060069085A1 (en) Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
KR20070050966A (en) Method for the production of dihydropteridinones
JP2019505531A (en) Process for preparing pyrrolo [3,2-d] pyrimidine compounds and intermediates thereof
EP3658547B1 (en) Process for preparing n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
JP3176137B2 (en) Biuret derivative
WO2004050088A1 (en) Jnk inhibitor
JP7502997B6 (en) Novel method for the synthesis of phenoxydiaminopyrimidine compounds
HU211773B (en) Process for producing dialkyl-(2,3-pyridinedicarboxylate) derivatives
EP2358670B1 (en) A process for the preparation of tert-butyl (R)-3-vinylpyrrolidine-1-carboxylate and intermediates therefor
JPH0640994A (en) New tetralone with pharmaceutical activity
US7169935B2 (en) Process for preparing heterocyclic indene analogs
EP1124805B1 (en) Method for producing 4-[(2',5'- diamino-6'- halopyrimidine- 4'-yl)amino]- cyclopent- 2-enylmethanols
JPH05112588A (en) Process for manufacturing acrylaminomethanesulfonic acid
WO2019219620A1 (en) Intermediates and processes for the preparation of linagliptin and its salts
US5087732A (en) Glutaric acid derivatives and preparation thereof
JP4307996B2 (en) Process for producing 4-methylamino-4-phenylpiperidine
US4999351A (en) 7-aryl and heteroaryl ethers of desacetylforskolin
US5260467A (en) Glutaric acid derivatives and preparation thereof
JPH083142A (en) 5-phenylpyrimidine compound
HU194169B (en) Process for producing substituted piperidines
JP2003514908A (en) Methods and intermediates directed to tetrahydro- [1,8] -naphthyridine
US5374634A (en) Pyridine derivatives
US5177207A (en) 7-aryl and heteroaryl ethers of desacetylforskolin

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees